Product Datasheet
VCL Antibody
Catalog Number: 32418
Technical:tech@swbio.com
Information:info@swbio.com
Description
- Swiss-Prot No.:
- Swiss-Prot:P18206
NCBI Gene ID:7414
- Form of Antibody:
- Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
- Immunogen:
- Recombinant protein of human VCL.
- reactivity:
- Human,Mouse,Rat
- appl_detail:
- WB 1:500 - 1:2000
IHC 1:50 - 1:200
- other_names:
- MV; MVCL; CMD1W; CMH15;
- Purification:
- Antibodies were purified by affinity purification using immunogen.
- Specificity:
- The antibody detects endogenous level of total VCL protein.
- Background:
- Vinculin is a cytoskeletal protein that plays an important role in the regulation of focal adhesions and embryonic development (1-4). Three structural vinculin domains include an amino-terminal head, a short, flexible proline-rich region and a carboxy-terminal tail (1). In the inactive state, the head and tail domains of vinculin interact to form a closed confirmation. The open and active form of vinculin translocates to focal adhesions where it is thought to be involved in anchoring F-actin to the membrane and regulation of cell migration (2). Phospholipid binding to the tail domain and subsequent phosphorylation of vinculin at Ser1033 and Ser1045 by PKC-α and Tyr100 and Tyr1065 by Src kinases weakens the head-tail interaction (5,6). This change in vinculin allows the binding of a number of other proteins, including talin, α-actinin and paxillin, which disrupts the head-tail interaction and initiates the conformational change from the inactive to active state (2,4). Vinculin deficiencies are associated with a decrease in cell adhesion and an increase in cell motility, suggesting a possible role in metastatic growth (7,8). This is supported by a recently demonstrated relationship between decreased vinculin expression and increased carcinogenesis and metastasis in colorectal carcinoma (9).
© Signalway Biotechnology All Rights Reserved.